NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route (Ascending) | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
55700-0631-30 | 55700-0631 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 25, 2018 | In Use | |
67296-1562-03 | 67296-1562 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 1, 2018 | In Use | |
70518-1042-00 | 70518-1042 | Ondansetron hydrochloride | Ondansetron hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | March 1, 2018 | May 11, 2020 | In Use |
71332-0005-01 | 71332-0005 | Olutasidenib | REZLIDHIA | 150.0 mg/1 | Chemotherapy | Enzyme Inhibitor | IDH1 | Oral | Dec. 1, 2022 | In Use | |
00615-8438-39 | 00615-8438 | PREDNISONE | Prednisone | 1.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 1, 2022 | In Use | |
00615-8439-05 | 00615-8439 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct. 6, 2022 | In Use | |
00615-8439-39 | 00615-8439 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct. 6, 2022 | In Use | |
00615-8440-05 | 00615-8440 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct. 27, 2022 | In Use | |
00615-8440-39 | 00615-8440 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct. 27, 2022 | In Use | |
16571-0817-02 | 16571-0817 | Temozolomide | TEMOZOLOMIDE | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 4, 2022 | In Use | |
16571-0817-51 | 16571-0817 | Temozolomide | TEMOZOLOMIDE | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 4, 2022 | In Use | |
16571-0817-41 | 16571-0817 | Temozolomide | TEMOZOLOMIDE | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 4, 2022 | In Use | |
16571-0818-02 | 16571-0818 | Temozolomide | TEMOZOLOMIDE | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 4, 2022 | In Use | |
16571-0818-51 | 16571-0818 | Temozolomide | TEMOZOLOMIDE | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 4, 2022 | In Use | |
16571-0818-41 | 16571-0818 | Temozolomide | TEMOZOLOMIDE | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 4, 2022 | In Use | |
16571-0819-02 | 16571-0819 | Temozolomide | TEMOZOLOMIDE | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 4, 2022 | In Use | |
16571-0819-51 | 16571-0819 | Temozolomide | TEMOZOLOMIDE | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 4, 2022 | In Use | |
16571-0819-41 | 16571-0819 | Temozolomide | TEMOZOLOMIDE | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 4, 2022 | In Use | |
16571-0820-02 | 16571-0820 | Temozolomide | TEMOZOLOMIDE | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 4, 2022 | In Use | |
16571-0820-51 | 16571-0820 | Temozolomide | TEMOZOLOMIDE | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 4, 2022 | In Use | |
16571-0820-41 | 16571-0820 | Temozolomide | TEMOZOLOMIDE | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 4, 2022 | In Use | |
16571-0821-02 | 16571-0821 | Temozolomide | TEMOZOLOMIDE | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 4, 2022 | In Use | |
16571-0821-51 | 16571-0821 | Temozolomide | TEMOZOLOMIDE | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 4, 2022 | In Use | |
16571-0821-41 | 16571-0821 | Temozolomide | TEMOZOLOMIDE | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 4, 2022 | In Use | |
43598-0045-28 | 43598-0045 | SUNITINIB MALATE | SUNITINIB MALATE | 12.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Nov. 30, 2022 | In Use | |
43598-0045-63 | 43598-0045 | SUNITINIB MALATE | SUNITINIB MALATE | 12.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Nov. 30, 2022 | In Use | |
43598-0046-28 | 43598-0046 | SUNITINIB MALATE | SUNITINIB MALATE | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Nov. 30, 2022 | In Use | |
43598-0046-63 | 43598-0046 | SUNITINIB MALATE | SUNITINIB MALATE | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Nov. 30, 2022 | In Use | |
43598-0047-28 | 43598-0047 | SUNITINIB MALATE | SUNITINIB MALATE | 37.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Nov. 30, 2022 | In Use | |
43598-0047-63 | 43598-0047 | SUNITINIB MALATE | SUNITINIB MALATE | 37.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Nov. 30, 2022 | In Use | |
43598-0048-28 | 43598-0048 | SUNITINIB MALATE | SUNITINIB MALATE | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Nov. 30, 2022 | In Use | |
43598-0048-63 | 43598-0048 | SUNITINIB MALATE | SUNITINIB MALATE | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Nov. 30, 2022 | In Use | |
00904-7266-61 | 00904-7266 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 2, 2022 | In Use | |
69238-2122-09 | 69238-2122 | Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 15.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct. 27, 2022 | In Use | |
50090-6225-00 | 50090-6225 | Prednisone | Prednisone | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 14, 2022 | In Use | |
50090-6259-00 | 50090-6259 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 7, 2022 | In Use | |
82009-0061-05 | 82009-0061 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov. 21, 2022 | In Use | |
71335-2181-01 | 71335-2181 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Oct. 25, 2022 | In Use | ||
71335-2181-02 | 71335-2181 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Oct. 25, 2022 | In Use | ||
71335-2181-03 | 71335-2181 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Oct. 25, 2022 | In Use | ||
46708-0618-31 | 46708-0618 | Cyclophosphamide | Cyclophosphamide | 25.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | Nov. 23, 2022 | In Use | |
46708-0619-31 | 46708-0619 | Cyclophosphamide | Cyclophosphamide | 50.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | Nov. 23, 2022 | In Use | |
49884-0128-91 | 49884-0128 | Everolimus | Everolimus | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Nov. 29, 2022 | In Use | |
62332-0618-31 | 62332-0618 | Cyclophosphamide | Cyclophosphamide | 25.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | Nov. 23, 2022 | In Use | |
62332-0619-31 | 62332-0619 | Cyclophosphamide | Cyclophosphamide | 50.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | Nov. 23, 2022 | In Use | |
00054-0143-07 | 00054-0143 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 24, 2008 | In Use | |
00054-0143-08 | 00054-0143 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec. 31, 2007 | In Use | |
00054-0143-87 | 00054-0143 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 24, 2008 | In Use | |
00143-1202-01 | 00143-1202 | Cortisone Acetate | Cortisone Acetate | 25.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | June 13, 1972 | In Use | |
00378-7131-93 | 00378-7131 | erlotinib hydrochloride | Erlotinib Hydrochloride | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 9, 2019 | Nov. 30, 2022 | No Longer Used |
Found 10,000 results in 6 milliseconds — Export these results